Cargando…

Impact of hepatitis C virus core mutations on the response to interferon-based treatment in chronic hepatitis C

AIM: To determine whether hepatitis C virus (HCV) core substitutions play a role in the response to interferon-based treatment in Caucasian patients. METHODS: One hundred eight HCV chronically infected patients initiating treatment with pegylated IFN plus ribavirin for 48 wk were tested for baseline...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sultana, Camelia, Oprişan, Gabriela, Teleman, Monica Delia, Dinu, Sorin, Oprea, Cristiana, Voiculescu, Mihai, Ruta, Simona
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2016
Materias:	Observational Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055871/ https://www.ncbi.nlm.nih.gov/pubmed/27729747 http://dx.doi.org/10.3748/wjg.v22.i37.8406

Ejemplares similares

Hepatitis B Virus Genotypes and Antiviral Resistance Mutations in Romanian HIV-HBV Co-Infected Patients
por: Sultana, Camelia, et al.
Publicado: (2022)

Serum Iron Markers in Patients With Chronic Hepatitis C Infection
por: Vagu, Codruta, et al.
Publicado: (2013)

Predictors of Chronic Hepatitis C Evolution in HIV Co-Infected Patients From Romania
por: Sultana, Camelia, et al.
Publicado: (2013)

Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country
por: Hlaing, Naomi Khaing Than, et al.
Publicado: (2016)

Interferon-free treatments in patients with hepatitis C genotype 1-4 infections in a real-world setting
por: Ramos, Huascar, et al.
Publicado: (2017)

Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era
por: Brzdęk, Michał, et al.
Publicado: (2023)

Incidence of Type 2 Diabetes in Patients With Chronic Hepatitis C Receiving Interferon-Based Therapy
por: Tsai, Ming-Chieh, et al.
Publicado: (2020)

CD4(+) T cells and natural killer cells: Biomarkers for hepatic fibrosis in human immunodeficiency virus/hepatitis C virus-coinfected patients
por: Laufer, Natalia, et al.
Publicado: (2017)

Alarming increase in tuberculosis and hepatitis C virus (HCV) among HIV infected intravenous drug users
por: Oprea, Cristiana, et al.
Publicado: (2014)

Occult hepatitis B virus infection is not associated with disease progression of chronic hepatitis C virus infection
por: Cho, Junhyeon, et al.
Publicado: (2016)

High prevalence of occult hepatitis C infection in predialysis patients
por: Sette, Luís Henrique Bezerra Cavalcanti, et al.
Publicado: (2019)

New real-time-PCR method to identify single point mutations in hepatitis C virus
por: Chen, Qian, et al.
Publicado: (2016)

Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new Direct-Acting Antiviral agents
por: Damiani, Giovanni, et al.
Publicado: (2018)

Mortality associated with hepatitis C and hepatitis B virus infection: A nationwide study on multiple causes of death data
por: Fedeli, Ugo, et al.
Publicado: (2017)

Hepatitis C virus burden: Treating and educating people without prejudice
por: Merola, Elettra, et al.
Publicado: (2022)

Differential regulation of the Wnt/β-catenin pathway by hepatitis C virus recombinants expressing core from various genotypes
por: Aicher, Stephanie, et al.
Publicado: (2018)

Increased Risk of Intracerebral Hemorrhage Among Patients With Hepatitis C Virus Infection
por: Tseng, Chun-Hung, et al.
Publicado: (2015)

Management of betablocked patients after sustained virological response in hepatitis C cirrhosis
por: Abadía, Marta, et al.
Publicado: (2019)

Chronic hepatitis-C infection in COVID-19 patients is associated with in-hospital mortality
por: Ronderos, Diana, et al.
Publicado: (2021)

Effect of treating chronic hepatitis C with direct-acting antivirals on extrahepatic cutaneous manifestations
por: El Kassas, Mohamed, et al.
Publicado: (2020)

Effectiveness and safety of generic and brand direct acting antivirals for treatment of chronic hepatitis C
por: Abdulla, Maheeba, et al.
Publicado: (2022)

Detection of colorectal adenomas using artificial intelligence models in patients with chronic hepatitis C
por: Singh, Yuvaraj, et al.
Publicado: (2023)

Psoriasis and Hepatitis C: Improvement with Interferon
por: Habte-Gabr, Eyassu, et al.
Publicado: (2011)

Attempt to calculate the prevalence and features of chronic hepatitis C infection in Tuscany using administrative data
por: Silvestri, Caterina, et al.
Publicado: (2016)

Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus
por: Rupp, Christian, et al.
Publicado: (2018)

Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis
por: Rinaldi, Luca, et al.
Publicado: (2017)

Concordance of non-invasive mechanical and serum tests for liver fibrosis evaluation in chronic hepatitis C
por: Paranaguá-Vezozzo, Denise C, et al.
Publicado: (2017)

Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection
por: Bichoupan, Kian, et al.
Publicado: (2017)

Monitoring hepatitis C virus treatment rates in an Opioid Treatment Program: A longitudinal study
por: Sanvisens, Arantza, et al.
Publicado: (2020)

Dried blood spot sampling as an alternative for the improvement of hepatitis B and C diagnosis in key populations
por: Flores, Geane Lopes, et al.
Publicado: (2021)

Hepatocellular carcinoma, decompensation, and mortality based on hepatitis C treatment: A prospective cohort study
por: Choi, Gwang Hyeon, et al.
Publicado: (2022)

Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

Add-on pegylated interferon augments hepatitis B surface antigen clearance vs continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen ≤ 1500 IU/mL: An observational study
por: Wu, Feng-Ping, et al.
Publicado: (2020)

Liver decompensation predicts ribavirin overexposure in hepatitis C virus patients treated with direct-acting antivirals
por: Guardigni, Viola, et al.
Publicado: (2017)

M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals
por: Saleh, Shereen A, et al.
Publicado: (2020)

Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders
por: Dybowska, Dorota, et al.
Publicado: (2023)

Hepatitis C virus core protein substitutions affect the response to pegylated-interferon and ribavirin therapy
por: Alhamlan, Fatimah S, et al.
Publicado: (2014)

Novel non-invasive biological predictive index for liver fibrosis in hepatitis C virus genotype 4 patients
por: Khattab, Mahmoud, et al.
Publicado: (2016)

Hepatitis C virus eradication with directly acting antivirals improves health-related quality of life and psychological symptoms
por: Nardelli, Silvia, et al.
Publicado: (2019)

Hepatitis D virus dual-infection among Chinese hepatitis B patient related to hepatitis B surface antigen, hepatitis B virus DNA and age
por: Zi, Jun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_80iiv7c36gkdtqvi51rfg7g33q